Close Menu

By Justin Petrone

Agilent Technologies continues to engage the US Food and Drug Administration about the optimal path forward for its microarrays that are used in constitutional and cancer cytogenetics, a company executive said this week.

In the meantime, Agilent continues to build resources to gain FDA clearance for arrays and other products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

Aug
13
Sponsored by
10x Genomics

This webinar will discuss a study that combined single-cell gene expression and spatial gene expression to understand the evolution of sepsis in the kidney at the cellular and molecular level.